# Christian Schneider

> Christian Schneider is a Series B investor at Vesalius Biocapital Partners backing Medical. See 6 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Vesalius Biocapital Partners](https://shizune.co/investors/profile/vesalius-biocapital-partners)
- Location: Strassen, Luxembourg
- Total investments: 6
- Last investment: May 2024
- Lead investor: 50%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/christian-schneider-218a0149

Christian Schneider is a Series B investor at Vesalius Biocapital Partners in Strassen focused on Medical and Health Care. Christian Schneider has extensive work and investment experience in the areas of diagnostics, medtech and therapeutics from 18 years in positions of increasing responsibility in the life science and venture capital industry.At Boehringer Mannheim / Roche (Germany, 1992-1995), he developed the first fully automated test for a new prostatecancer marker, free PSA, which is marketed by Roche worldwide.At Centocor / Johnson&Johnson (USA, 1995-2000), he led the development of a panel of tumor markers in a transatlantic collaboration between Centocor and Boehringer Mannheim/Roche. Later, as a business developer and external research manager, he negotiated license agreements, set up budgets, and managed biopharma development projects.As a managing partner of venture capital firm PolyTechnos (Germany 2001-2008), he was directly responsible for the investments in and the IPOs of OncoMethylome Sciences (Euronext, 2006: ONCO), Devgen (Euronext, 2005: DEVG) and Jerini (Frankfurt, 2005: JI4). As a support partner, he was further responsible for the investments and exits of Addex (SWIX, 2007: ADXN) and BiPar (USD 500 m trade-sale to Sanofi-Aventis, 2009). He further served as an independent director on the boards of Immunogenes, HepaWash and MagnaMedics. Christian joined Vesalius in 2008. He is fluent in English and German.Christian holds a doctorate degree in veterinary medicine (1992) and a PhD in immunology (1995), both from the University of Munich, Germany, and an MBA with focus on healthcare administration from Penn State University, Pennsylvania (1999).

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 1 | 17% |
| Health Care | 1 | 17% |
| Therapeutics | 1 | 17% |
| Biotechnology | 1 | 17% |
| Collaboration | 1 | 17% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 2 | 33% |
| Series C | 2 | 33% |
| Series A | 1 | 17% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Germany | 1 | 17% |
| Switzerland | 1 | 17% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Memo Therapeutics | Memo Therapeutics AG (MEMO) is an innovator in the field of antibody discovery and immune repertoire analysis.Its MemoMAB™ platform creates a recombinant in vitro copy of an individual’s B cell / antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’simmune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. This leads to entirely new possibilities in immune repertoire analysis and antibody discovery.MemoMAB™ is deployed in proprietary antibody lead discovery programs and is made available in collaborations. | $22M | Series C | May 07, 2024 |  |
| Memo Therapeutics | Memo Therapeutics AG (MEMO) is an innovator in the field of antibody discovery and immune repertoire analysis.Its MemoMAB™ platform creates a recombinant in vitro copy of an individual’s B cell / antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’simmune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. This leads to entirely new possibilities in immune repertoire analysis and antibody discovery.MemoMAB™ is deployed in proprietary antibody lead discovery programs and is made available in collaborations. | $27.6M | Series C | Nov 02, 2023 |  |
| Memo Therapeutics | Memo Therapeutics AG (MEMO) is an innovator in the field of antibody discovery and immune repertoire analysis.Its MemoMAB™ platform creates a recombinant in vitro copy of an individual’s B cell / antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’simmune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. This leads to entirely new possibilities in immune repertoire analysis and antibody discovery.MemoMAB™ is deployed in proprietary antibody lead discovery programs and is made available in collaborations. | $24.9M | Series B | Feb 16, 2022 |  |
| OMEICOS Therapeutics | OMEICOS Therapeutics is developing a novel, first-in-class, small molecule utilizing a new Mode of Action. OMEICOS' novel therapeutic strategy is based upon the discovery of natural metabolites of omega-3 fatty acids that mediate a strong anti-arrhythmic effect. In contrast to all other anti-arrhythmic drugs, OMEICOS' substances activatean endogenous cardio-protective signaling pathway that not only stabilizes the heart rhythm but shall provide curative effects to the diseased organ by preventing its electrical and structural remodeling. | $18.6M | Series C | Nov 02, 2018 |  |
| OMEICOS Therapeutics | OMEICOS Therapeutics is developing a novel, first-in-class, small molecule utilizing a new Mode of Action. OMEICOS' novel therapeutic strategy is based upon the discovery of natural metabolites of omega-3 fatty acids that mediate a strong anti-arrhythmic effect. In contrast to all other anti-arrhythmic drugs, OMEICOS' substances activatean endogenous cardio-protective signaling pathway that not only stabilizes the heart rhythm but shall provide curative effects to the diseased organ by preventing its electrical and structural remodeling. | $9.1M | Series B | Mar 01, 2017 |  |
| OMEICOS Therapeutics | OMEICOS Therapeutics is developing a novel, first-in-class, small molecule utilizing a new Mode of Action. OMEICOS' novel therapeutic strategy is based upon the discovery of natural metabolites of omega-3 fatty acids that mediate a strong anti-arrhythmic effect. In contrast to all other anti-arrhythmic drugs, OMEICOS' substances activatean endogenous cardio-protective signaling pathway that not only stabilizes the heart rhythm but shall provide curative effects to the diseased organ by preventing its electrical and structural remodeling. | $6.8M | Series A | Apr 15, 2015 |  |

6 of 6 investments shown.

## Co-investors
- [Swisscanto Private Equity](https://shizune.co/investors/profile/swisscanto-invest) — VC Fund, 4 deals together
- [Fresenius Medical Care](https://shizune.co/investors/profile/fresenius-medical-care) — VC Fund, 3 deals together
- [GF Group Holding](https://shizune.co/investors/profile/gf-group-holding) — VC Fund, 3 deals together
- [KfW](https://shizune.co/investors/profile/kfw) — VC Fund, 3 deals together
- [SMS Group](https://shizune.co/investors/profile/smsgroup) — VC Fund, 3 deals together
- [VC Fonds Technologie Berlin](https://shizune.co/investors/profile/vc-fonds-technologie-berlin) — VC Fund, 3 deals together

## About Vesalius Biocapital Partners

VC Fund · Strassen, Luxembourg

Vesalius Biocapital Partners invests in companies active in human health through venture capital funds raised since 2007. They have contributed to developing 20 companies since inception.With more than € 150 million under management in two funds. Vesalius Biocapital Partners plays the role of lead investor in the large majority of its financingrounds.Their companies are based in Europe allowing easy interaction with management.They invest in all stages of development and do not shy away from relatively early-stage projects with a sound proprietary technology and corresponding IP, unique team skills and a clear competitive edge based on solid data.

5 contacts available at Vesalius Biocapital Partners.

| Name | Title | Profile |
| --- | --- | --- |
| Fei Tian | Analyst | https://shizune.co/investors/profile/fei-tian |
| Guy Geldhof | Partner | https://shizune.co/investors/profile/guy-geldhof |
| Stephane Verdood | Managing Partner | https://shizune.co/investors/profile/stephane-verdood |
| Alain Parthoens | Managing Partner | https://shizune.co/investors/profile/alain-parthoens |
| Christian Schneider | Managing Partner | https://shizune.co/investors/profile/christian-schneider |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Christian Schneider invest in?

Christian Schneider invests primarily in Medical, Health Care and Therapeutics startups, most often at Series B and Series C stage. Most of the 6 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Christian Schneider last invest?

The most recent investment recorded for Christian Schneider closed in May 2024. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co